Taipei Exchange - Delayed Quote TWD

TaiRx, Inc. (6580.TWO)

Compare
26.00
+0.50
+(1.96%)
At close: 2:59:24 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Du-Shieng Chien Ph.D. Co-Founder, President, CEO & Director -- -- --
Mr. Huang Shiqi M.A. CFO & Accounting Supervisor -- -- --
Dr. Yi-Wen Chu Ph.D. Senior VP & Director -- -- --

TaiRx, Inc.

No. 66, San-Chung Road
6th Floor-1 Nankang Business Park
Taipei City, 11502
Taiwan
886 2 2653 5007 https://www.trx.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology

Description

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.

Corporate Governance

TaiRx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers